Genmab A/S (NASDAQ:GMAB – Free Report) – Leerink Partnrs raised their FY2024 earnings per share (EPS) estimates for shares of Genmab A/S in a analysis notice issued to buyers on Wednesday, November sixth. Leerink Partnrs analyst J. Chang now forecasts that the corporate will put up earnings per share of $1.29 for the 12 months, up from their earlier estimate of $1.15. The consensus estimate for Genmab A/S’s present full-year earnings is $1.31 per share. Leerink Partnrs additionally issued estimates for Genmab A/S’s This fall 2024 earnings at $0.40 EPS and FY2025 earnings at $1.58 EPS.
Genmab A/S (NASDAQ:GMAB – Get Free Report) final posted its quarterly earnings outcomes on Wednesday, November sixth. The corporate reported $0.29 earnings per share for the quarter, lacking analysts’ consensus estimates of $0.32 by ($0.03). Genmab A/S had a return on fairness of 14.64% and a web margin of 23.49%. The enterprise had income of $816.10 million for the quarter, in comparison with analyst estimates of $838.20 million. Throughout the identical quarter within the prior 12 months, the agency earned $0.47 EPS.
GMAB has been the subject of a number of different reviews. JPMorgan Chase & Co. reiterated a “impartial” ranking on shares of Genmab A/S in a analysis notice on Tuesday, August twentieth. Royal Financial institution of Canada upgraded Genmab A/S from a “sector carry out” ranking to an “outperform” ranking in a analysis report on Monday, July fifteenth. BMO Capital Markets reissued an “outperform” ranking and set a $48.00 worth goal (up from $46.00) on shares of Genmab A/S in a report on Friday. Truist Monetary lowered their goal worth on shares of Genmab A/S from $53.00 to $50.00 and set a “purchase” ranking on the inventory in a report on Monday, September ninth. Lastly, Redburn Atlantic began protection on shares of Genmab A/S in a report on Tuesday, October eighth. They set a “purchase” ranking for the corporate. One equities analysis analyst has rated the inventory with a promote ranking, two have issued a maintain ranking and 7 have issued a purchase ranking to the corporate’s inventory. Based on information from MarketBeat.com, the corporate has a mean ranking of “Reasonable Purchase” and a mean goal worth of $45.20.
View Our Newest Analysis Report on Genmab A/S
Genmab A/S Inventory Up 0.5 %
NASDAQ GMAB opened at $23.20 on Monday. Genmab A/S has a twelve month low of $21.90 and a twelve month excessive of $32.89. The inventory has a market cap of $15.35 billion, a P/E ratio of twenty-two.50, a PEG ratio of 0.68 and a beta of 0.99. The corporate’s 50-day easy transferring common is $24.39 and its 200 day easy transferring common is $26.38.
Hedge Funds Weigh In On Genmab A/S
Numerous institutional buyers have lately modified their holdings of the inventory. Russell Investments Group Ltd. raised its place in Genmab A/S by 137.7% within the 1st quarter. Russell Investments Group Ltd. now owns 939 shares of the corporate’s inventory value $28,000 after buying a further 544 shares over the last quarter. Allspring International Investments Holdings LLC purchased a brand new stake in shares of Genmab A/S throughout the first quarter value $43,000. Blue Belief Inc. lifted its stake in shares of Genmab A/S by 892.0% throughout the third quarter. Blue Belief Inc. now owns 4,315 shares of the corporate’s inventory valued at $108,000 after buying a further 3,880 shares throughout the interval. Headlands Applied sciences LLC boosted its holdings in Genmab A/S by 1,702.8% within the second quarter. Headlands Applied sciences LLC now owns 5,138 shares of the corporate’s inventory valued at $129,000 after buying a further 4,853 shares over the last quarter. Lastly, Benjamin F. Edwards & Firm Inc. elevated its place in Genmab A/S by 7.1% within the second quarter. Benjamin F. Edwards & Firm Inc. now owns 7,227 shares of the corporate’s inventory value $182,000 after buying a further 478 shares throughout the interval. 7.07% of the inventory is owned by institutional buyers.
Genmab A/S Firm Profile
(Get Free Report)
Genmab A/S develops antibody therapeutics for the therapy of most cancers and different ailments primarily in Denmark. The corporate markets DARZALEX, a human monoclonal antibody for the therapy of sufferers with a number of myeloma (MM); teprotumumab for the therapy of thyroid eye illness; and Amivantamab for superior or metastatic gastric or esophageal most cancers and NSCLC.
See Additionally
Obtain Information & Scores for Genmab A/S Each day – Enter your e mail tackle under to obtain a concise every day abstract of the newest information and analysts’ scores for Genmab A/S and associated corporations with MarketBeat.com’s FREE every day e mail publication.
